

Tacrolimus monotherapy for uveitis

Submission date 15/04/2008	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 16/04/2008	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 28/03/2012	Condition category Eye Diseases	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Richard Lee

Contact details
Academic Unit of Ophthalmology
Bristol Eye Hospital
Lower Maudlin Street
Bristol
United Kingdom
BS1 2LX
+44 (0)117 928 4949
richard.lee@bristol.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
OP/2004/1733

Study information

Scientific Title

Dual steroid and tacrolimus therapy versus steroid withdrawal and tacrolimus therapy in the treatment of posterior segment intraocular inflammation (uveitis)

Study objectives

Tacrolimus monotherapy is not inferior to tacrolimus and prednisolone for the maintenance of uveitis remission.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from North Somerset and South Bristol Research Ethics Committee on the 8th March 2004 (ref: E5862).

Study design

Dual-centre, randomised, non-inferiority, open-label trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Uveitis

Interventions

1. Oral tacrolimus (target trough serum level 8 - 12 ng/ml) only
2. Oral tacrolimus (target trough serum level 8 - 12 ng/ml) and oral prednisolone (7.5 - 10 mg daily)

Frequency of oral tacrolimus administration is the same for both trial arms. It is administered twice daily, however the oral dose prescribed to achieve the target serum levels varies from patient to patient. Treatment duration and follow-up are until study completion (i.e., nine months post randomisation), or withdrawal.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Tacrolimus, prednisolone

Primary outcome measure

Change in logarithm of the minimum angle of resolution (LogMAR) visual acuity (VA) between randomisation and study completion or withdrawal.

Secondary outcome measures

1. Rate of study withdrawal post-randomisation due to either treatment inefficacy (disease reactivation) or intolerance
2. Change in the following measures of disease severity between randomisation and study completion or withdrawal:
 - 2.1. Binocular indirect ophthalmoscopy score
 - 2.2. Anterior chamber cell grade
 - 2.3. Retinal vasculitis score
 - 2.4. Grade of optic disc swelling
 - 2.5. Chorioretinal infiltrate
3. Change in the following assessments of treatment tolerance between randomisation and study completion or withdrawal:
 - 3.1. Rate of onset of hypocholesterolemia, hypoglycaemia, hypertension, hypomagnesaemia and greater than or equal to 30% increase in serum creatinine concentration
 - 3.2. Rate of onset of adverse events - overall by system (e.g. nervous system) and by description (e.g. tremor)
 - 3.3. Rate of increase in intraocular pressure (IOP) to greater than 24 mmHg
4. Proportion of patients withdrawn post-enrolment and pre-randomisation for treatment inefficacy or intolerance
5. Change in quality of life in 3, 6 and 12 months after study enrolment, as assessed by the 36-item short form health survey (SF-36) and vision core module 1 (VCM1) scores

Overall study start date

01/05/2004

Completion date

01/12/2008

Eligibility

Key inclusion criteria

Patients with sight-threatening non-infectious posterior intraocular inflammation (PSII) who:

1. Are unable to reduce their prednisone dose to less than 10 mg daily without disease relapse
2. Require recurrent high dose steroid rescue for recurrent relapsing disease
3. Have severe sight-threatening disease warranting immediate institution of combination immunotherapy (high dose prednisone and a second line agent)
4. Are greater than or equal to 18 years old, either sex, and able to give informed consent

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

40

Key exclusion criteria

1. Pregnancy or lactation
2. Female patients of child bearing age who are unwilling or unable to maintain effective birth control during the study
3. Diabetes mellitus (except steroid induced)
4. Significant and unstable renal disease (creatinine outside the local laboratories reference range on two consecutive occasions)
5. Participating in another clinical trial or has been taking an investigational drug in the past 28 days
6. Unlikely to comply with the visits scheduled in the protocol
7. Live vaccinations within three months of study entry
8. Previous adverse event associated with, or contra-indication to, either prednisolone or tacrolimus
9. Concurrent use of other immunosuppressive or cytotoxic agents
10. Previous tuberculosis
11. Shingles within the past three months
12. Human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS), including current or previous history of opportunistic infections such as cytomegalovirus (CMV), active *Pneumocystis carinii*, atypical mycobacterium
13. Recent history of substance abuse (drug or alcohol)
14. Use of cyclosporin A within the last three months
15. Serious infections, such as hepatitis, pneumonia, pyelonephritis in the previous three months

Date of first enrolment

01/05/2004

Date of final enrolment

01/12/2008

Locations**Countries of recruitment**

England

United Kingdom

Study participating centre

Academic Unit of Ophthalmology
Bristol
United Kingdom
BS1 2LX

Sponsor information

Organisation

United Bristol Healthcare Trust (UK)

Sponsor details

Research and Effectiveness Department
UBHT Education Centre, Level 3
Upper Maudlin Street
Bristol
England
United Kingdom
BS2 8AE

Sponsor type

Hospital/treatment centre

Website

<http://www.ubht.nhs.uk/>

ROR

<https://ror.org/04nm1cv11>

Funder(s)

Funder type

Industry

Funder Name

Fujisawa Pharma Co Ltd (UK)

Funder Name

NHS R&D support funding (UK)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/06/2012		Yes	No